Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 2:14:1109486.
doi: 10.3389/fimmu.2023.1109486. eCollection 2023.

Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19

Marion F Gruber  1 , Steven Rubin  2 , Philip R Krause  3
Affiliations

Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19

Marion F Gruber et al. Front Immunol. .

Abstract

Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV) and Marburg virus (MARV), are members of the Filoviridae family that can cause severe disease and death in humans and animals. The reemergence of Ebola, Sudan and Marburg virus disease highlight the need for continued availability of safe and effectives vaccines as well as development of new vaccines. While randomized controlled trials using disease endpoints provide the most robust assessment of vaccine effectiveness, challenges to this approach include the unpredictable size, location, occurrence and duration of filovirus disease outbreaks. Thus, other approaches to demonstrating vaccine effectiveness have been considered. These approaches are discussed using examples of preventive vaccines against other infectious diseases. In addition, this article proposes a clinical immunobridging strategy using licensed EBOV vaccines as comparators for demonstrating the effectiveness of filovirus vaccine candidates that are based on the same licensed vaccine platform technology.

Keywords: Ebola; Marburg; Sudan; correlates of protection; effectiveness; filovirus; immunobridging; vaccine.

PubMed Disclaimer

Conflict of interest statement

SR is currently an employee of GSK group of companies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Approaches to demonstrating the effectiveness of preventive vaccines.
See this image and copyright information in PMC

References

    1. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. . Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med (2014) 371(15):1418–25. doi: 10.1056/NEJMoa1404505 - DOI - PubMed
    1. Feldmann H, Slenczka W, Klenk HD. Emerging and reemerging of filoviruses. Arch Virol Suppl. (1996) 11:77–100. doi: 10.1007/978-3-7091-7482-1_9 - DOI - PubMed
    1. Hunt CL, Lennemann NJ, Maury W. Filovirus entry: a novelty in the viral fusion world. Viruses (2012) 4(2):258–75. doi: 10.3390/v4020258 - DOI - PMC - PubMed
    1. Herbert A. Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo. mBio (2015) 6(3):e00565-15. doi: 10.1128/mBio.00565-15 - DOI - PMC - PubMed
    1. Mohamadzadeh M LC, Schmaljohn A. How Ebola and marburg viruses battle the immune system. Nature Reviews immunology (2007) 7:556–66. Nature Publishing Group. doi: 10.1038/nri2098 - DOI - PubMed

Publication types